Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

This study is testing a new combination of drugs for people with advanced, stage 4 lung cancer that has stopped responding to previous treatments. Researchers want to see if adding immune-boosting medications to standard chemotherapy can help the body fight the cancer more effectively than chemotherapy alone.

You may be eligible if you are at least 18 years old and have stage 4 lung cancer that has continued to grow after you already received standard chemotherapy and immunotherapy. Because this study has specific medical requirements, doctors will review your history to ensure it is a safe fit for you.

Participants will be placed into groups by chance. Some will receive the new combination of drugs, while others will receive standard chemotherapy, allowing doctors to compare the results and see which approach works best.

This study is currently recruiting volunteers at medical centers in Arkansas and California. Your doctor can help you determine if one of these locations is accessible for you.